• New name and branding to be announced in the coming weeks, better aligned with the Company's scientific mandate and all business segments
• Name change resolution to be voted on by shareholders at the upcoming Annual General and Special Meeting ("AGSM") on May 11, 2026
• Company urges all shareholders to vote IN FAVOUR of the name change resolution to support the rebranding exercise
• Rebranding reflects the combined focus on clinical research, GMP manufacturing, FDA-aligned drug development, and the advancement of patented botanical psychedelic drug candidates including PEX010

Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company") today announced its intention to undertake a corporate rebranding, including a change of the Company's name, following the closing of the acquisition of Filament Health Corp. ("Filament") (the "Transaction"). The proposed rebranding remains subject to shareholder approval of a name change resolution at the Company's upcoming Annual General and Special Meeting ("AGSM") scheduled for May 11, 2026.

The decision to rebrand reflects the Company's significant strategic evolution since its founding. Following the closing of the Filament Transaction, the combined entity has operations in the research-driven, pharmaceutical-focused platform centered on the development of regulated psychedelic medicines across clinical, regulatory, and commercial channels, in addition to existing business segments. The current "Red Light Holland" name is no longer fully representative of the breadth of the Company's operations. A new name and brand identity will better position the Company to pursue all business segments and to be recognized as a serious participant in the pharmaceutical and life sciences space.

The closing of the Filament Transaction represented a defining milestone, bringing together Red Light's data collection and commercial infrastructure with Filament's established Good Manufacturing Practice ("GMP") production capabilities, regulatory engagement with the U.S. Food and Drug Administration ("FDA"), and a growing global clinical footprint. Central to the combined platform is Filament's lead drug candidate, PEX010, a botanical psilocybin formulation currently being evaluated across more than 70 clinical research sites worldwide in studies targeting serious mental health conditions, including depression, PTSD, substance use disorders, and cancer-related distress. A name and branding reflective of this expanded scientific mandate will be announced in the coming weeks.

Management Commentary

Todd Shapiro, Chief Executive Officer of the Company, commented: "The Filament Health transaction represents a transformative milestone for our Company, and the time has come for our name and brand to reflect the evolution of our business and the direction of our strategy.

Our progression from early, emerging markets to a disciplined, science-driven pharmaceutical platform has been both deliberate and substantial, supported by world-class clinical assets, patented drug candidates, and an expanding global research network.

We look forward to unveiling a new name and brand in the coming weeks. We urge all shareholders to vote IN FAVOUR of the name change resolution at the upcoming AGSM on May 11, 2026."

Shareholder Meeting and Name Change Resolution

The name change resolution will be presented to shareholders at the AGSM scheduled for May 11, 2026. Details of the proposed new name will be included in the Company's management information circular ("MIC"), which will be mailed and filed on SEDAR+ in advance of the AGSM. The name change remains subject to shareholder approval at the AGSM and any applicable regulatory approvals, including approval of the relevant stock exchanges.

The Company strongly encourages all registered and beneficial shareholders to review the MIC carefully and to vote IN FAVOUR of the name change resolution. Shareholders who have questions about how to vote their shares are invited to contact the Company's investor relations team at the contact information set out below.

Grants of RSUs

Pursuant to the Company's equity incentive plan (the "Plan") approved at the Company's annual, general and special meeting held on October 31, 2024, the Company granted 19,350,000 restricted stock units (the "RSUs") to certain officers, employees, and consultants of the Company, vesting over the next eighteen months.

The common shares of the Company ("Shares") underlying the RSUs are subject to a statutory four month and one day hold period, and such further restrictions as may apply under foreign securities laws.

Certain directors of the Company received 12,600,000 RSUs representing a related-party transaction under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The participation of the related party of the Company is exempt from the formal valuation and minority shareholder approval requirements provided under MI 61-101 in accordance with sections 5.5(a) and 5.7(1)(1) of MI 61-101, as neither the fair market value of the subject matter of the transaction, nor the consideration, exceed 25% of the Company's market capitalization.. The Company did not file a material change report related to the RSU grant more than 21 days before the grant as required by MI 61- 101 but believes that this shorter period is reasonable and necessary in the circumstances as the Company wishes to incentivize the retaining of key personnel as soon as possible.

Issuance of Shares for Debt Settlement

The Company also announces that its board of directors has approved the settlement of amounts owing to arm's length creditors through the issuance of Shares at the deemed price per share to be determined at time of settlement.

About Red Light Holland

Red Light Holland is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and R&D initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. Following the closing of the acquisition of Filament Health Corp., Filament is now a wholly owned subsidiary of the Company, bringing together its established Good Manufacturing Practice ("GMP") production capabilities, regulatory engagement with the U.S. Food and Drug Administration ("FDA"), and a growing global clinical footprint anchored by PEX010, a patented botanical psilocybin drug candidate. In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.

Cautionary Note Regarding Forward-Looking Statements

Certain information in this news release constitutes forward-looking information under applicable Canadian securities legislation. Any statements that are not statements of historical fact may be deemed to be forward-looking information. Forward-looking information is often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking information in this news release includes, but is not limited to, statements with respect to: the anticipated benefits of the Transaction; the Company's intention to rebrand and change its name; the anticipated timing of the announcement of a new name and branding; the expected presentation of the name change resolution at the AGSM and receipt of shareholder approval thereof; the expected regulatory approvals of the name change; the anticipated strategic priorities of the combined entity following the closing of the Transaction; and the continued clinical and commercial development of PEX010 and the Company's other intellectual property assets.

In particular, there can be no assurance that a name change will receive shareholder or regulatory approval, or that the new name and branding will be announced on the anticipated timeline. Forward-looking information is based on certain assumptions regarding Red Light, including assumptions regarding prevailing market conditions, and receipt of required approvals. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking information.

Forward-looking information also necessarily involves known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; the regulatory environment for psychedelic substances in Canada and internationally; the ability to retain key personnel following the Transaction; inability to access sufficient capital from internal and external sources; risks inherent in clinical drug development; the ability to realize the anticipated benefits of the Transaction; competition; currency and interest rate fluctuations; and the risk that a name change may not be permitted by the applicable stock exchanges. Readers are cautioned that the foregoing list is not exhaustive.

Forward-looking information contained in this news release is expressly qualified by this cautionary statement and reflects the expectations of Red Light as of the date hereof, and thus is subject to change thereafter. Red Light disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. This news release has been approved by the board of directors of Red Light Holland. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in Red Light's public filings and material change reports available on SEDAR+.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295736

Source: Red Light Holland Corp.